Benign Prostatic Hyperplasia

Slide 1 · Benign prostatic hyperplasia

Nodular glandular and stromal proliferation

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain the zonal origin and benign proliferative nature of BPH.

Trace the DHT–androgen receptor pathway and stromal–epithelial signaling.

Recognize gross and microscopic patterns of nodular hyperplasia.

Connect urethral obstruction with symptoms, complications and treatment targets.

Slide 3 · BPH is a benign nodular proliferation

Glandular epithelium

Fibromuscular stroma

BPH is also termed nodular hyperplasia.

Both glandular and fibromuscular stromal compartments expand.

The defining problem is location-associated urethral obstruction, not malignant growth.

Slide 4 · Prostate zones determine disease patterns

Urethra

Periurethral / transition

Outer regions shown for orientation

The transition zone lies close to the proximal urethra.

The peripheral zone accounts for most prostatic carcinomas.

Zonal location explains why BPH frequently obstructs urinary outflow.

Slide 5 · The normal gland has two epithelial layers

Schematic tissue architecture — not a photomicrograph

Secretory columnar cells form the inner luminal lining.

Basal cuboidal or flattened cells form an outer layer.

Fibromuscular stroma surrounds and separates glandular structures.

Slide 6 · BPH becomes increasingly common with age

>50 years

Most common benign prostatic disease in this age group

Up to 90%

Histologic evidence by age 80 years

Slide 7 · Clinical symptoms do not equal histologic prevalence

Histologic BPH

Symptomatic BPH

Benign nodules recognized in the prostate

Lower urinary tract symptoms attributed to obstruction

May be present without prominent symptoms

Depends on degree and effects of obstruction

Up to 90% by age 80 years (Robbins)

~30% have moderate–severe symptoms among US males of European descent >50 years (Robbins)

Slide 8 · BPH is not a premalignant lesion

Benign prostatic hyperplasia

Prostatic carcinoma

Benign glandular and stromal nodules

Malignant epithelial neoplasm

Mainly transition/periurethral zones

Most arise in peripheral zone

Urinary outlet compression is central

A distinct disease process, not progression from BPH

Slide 9 · Prostate growth depends on androgen signaling

Testosterone

Conversion to DHT

Androgen receptor

Growth-regulating genes

Testicular androgens support normal prostatic growth and survival.

BPH retains an androgen-dependent growth program.

Slide 10 · Type 2 5α-reductase makes DHT locally

Testosterone

Stromal 5α-reductase type 2

DHT

Type 2 5α-reductase is expressed mainly in stromal cells.

Prostatic epithelial cells do not express this isoenzyme in the Robbins account.

Slide 11 · Type 1 5α-reductase provides another DHT source

Skin / liver

DHT formation

Blood-borne DHT

Prostate

Type 1 activity in extraprostatic sites contributes DHT to circulation.

Skin and liver are examples of sites.

Slide 12 · DHT is more potent than testosterone at AR

Testosterone

Dihydrotestosterone (DHT)

Precursor of intraprostatic DHT

Principal androgen acting in the prostate

Binds androgen receptor

Higher AR affinity

Less stable ligand–receptor complex

Forms a more stable ligand–receptor complex

Slide 13 · Both stromal and epithelial cells express AR

Stromal compartment

AR activation → growth-factor production

Epithelial compartment

AR activation → growth/survival responses

The stromal and epithelial compartments both respond to DHT.

Their downstream responses interact through local growth-factor signaling.

Slide 14 · Activated AR translocates to the nucleus

DHT binds AR

AR enters nucleus

Gene transcription

Growth-factor network

DHT–AR binding triggers receptor movement from cytoplasm to nucleus.

Nuclear AR regulates transcription of androgen-dependent genes.

Slide 15 · AR regulates growth factors and receptors

DHT–AR complex

Androgen-responsive genes

FGF / TGF-β signaling

Growth-promoting programs are mediated indirectly as well as directly.

FGF-family factors and TGF-β are emphasized in the Robbins discussion.

Slide 16 · FGFs link stroma to epithelial growth

Stromal cells

Produce FGF-family signals

Epithelial cells

Receive local growth signals

Stromal fibroblast growth factors act through paracrine signaling.

This stromal–epithelial dialogue is established in prostatic development.

Slide 17 · BPH may reactivate developmental pathways

Embryonic growth program

Adult reactivation

Prostatic proliferation

FGF-dependent signaling is important in embryonic prostate development.

The same pathways may be reawakened in adult BPH.

Slide 18 · TGF-β has compartment-dependent effects

Mesenchymal/stromal cells

Epithelial cells

TGF-β can stimulate fibroblast and mesenchymal proliferation

TGF-β inhibits epithelial proliferation

Supports stromal expansion

Its direct effect is not uniformly growth promoting

Net BPH response requires multicellular context

Avoid equating every signal with mitogenesis

Slide 19 · The imbalance involves proliferation and death

Net accumulation of tissue

Increased stromal proliferation

Decreased epithelial cell death

Combined effect: Benign tissue accumulation

Increased stromal proliferation and reduced epithelial cell death.

The net result is accumulation of benign glandular and stromal tissue.

Slide 20 · Androgens are permissive, not the whole explanation

Androgen signaling is essential to the pathobiologic model.

The ultimate cause of BPH remains incompletely understood.

Additional influences, including estrogen pathways, shift local growth–death balance.

Slide 21 · Estrogens also influence prostatic growth

Estrogen-related inputs

Local signaling change

More proliferation relative to loss

Evidence supports an estrogen contribution to BPH.

The relevant outcome is a shift toward net cellular accumulation.

Slide 22 · ERα and ERβ exert opposing influences

Estrogen receptor α (ERα)

Estrogen receptor β (ERβ)

Proliferative influence in the Robbins model

Antiproliferative influence in the Robbins model

May favor cellular accumulation

May restrain cellular accumulation

Net balance depends on receptor context

Neither receptor acts in isolation

Slide 23 · Aromatase and prostaglandin E₂ participate

Aromatase-related signaling

Prostaglandin E₂ signaling

Altered growth–death balance

The source identifies aromatase expression among estrogen-related mechanisms.

Paracrine signaling through prostaglandin E₂ is also implicated.

Slide 24 · Integrated hormonal model of BPH

Androgens

Type 2 / type 1 5α-reductase → DHT → AR

Growth factors

FGFs and TGF-β act in stromal–epithelial context

Estrogens

ERα / ERβ, aromatase, prostaglandin E₂

This is a mechanistic model, not a single proven initiating event.

DHT/AR, growth factors and estrogen-related signaling converge on tissue accumulation.

Slide 25 · Hyperplasia arises in the transition zone

Urethra

Periurethral / transition

Outer regions shown for orientation

Transition and inner periurethral zones are characteristically affected.

A centrally located nodule has direct access to the prostatic urethra.

Slide 26 · Prostate weight may rise several-fold

~20 g

Approximate normal adult prostate weight

60–100 g

Common BPH enlargement: Approximately three- to five-fold

Slide 27 · Enlargement is often nodular rather than uniform

Schematic — not a gross specimen

Discrete hyperplastic nodules expand within the gland.

Gross and microscopic appearance varies with relative glandular and stromal content.

Slide 28 · Nodules narrow the urethral lumen

Open outlet

Patent urethral channel

BPH compression

Narrow slit-like lumen

Slide 29 · Gland-rich and stroma-rich nodules differ

Predominantly glandular

Predominantly fibromuscular

Yellow-pink and soft

Pale gray and firm

May exude milky prostatic fluid

Firm due to stromal predominance

Numerous glandular lumina

Greater smooth muscle / fibrous tissue contribution

Slide 30 · The gross glandular nodule is soft

Schematic — not a gross specimen

Gland-dominant nodules are described as yellow-pink.

Their soft cut surface may express milky white prostatic fluid.

Gross characteristics reflect the tissue composition of a nodule.

Slide 31 · The stromal nodule is comparatively firm

Schematic — not a gross specimen

Fibromuscular-rich nodules are pale gray and firm.

Cellular composition, not malignancy, accounts for this texture.

Grossly different nodules can coexist in the same enlarged gland.

Slide 32 · Microscopic glands span a range of sizes

Schematic tissue architecture — not a photomicrograph

A single nodule may contain small, large and cystically dilated glands.

Glandular size variation occurs amid proliferating stromal tissue.

Slide 33 · Some glands become cystically dilated

Schematic tissue architecture — not a photomicrograph

Marked glandular dilatation is an accepted BPH morphology.

Interpret dilatation in the setting of nodular, two-layered benign glands.

Slide 34 · Papillary epithelial infoldings are common

Schematic tissue architecture — not a photomicrograph

Luminal secretory epithelium may fold into the glandular space.

Such infoldings yield a papillary contour without implying cancer.

Slide 35 · BPH glands retain a basal cell layer

Schematic tissue architecture — not a photomicrograph

Luminal columnar secretory cells form an inner lining.

A cuboidal or flattened basal layer remains external to them.

Preserved bilayered architecture supports benign gland morphology.

Slide 36 · Bland spindle stromal cells separate glands

Schematic tissue architecture — not a photomicrograph

Stromal cells have bland spindle-shaped morphology in typical BPH.

Fibromuscular stroma is an active constituent of the hyperplastic nodule.

Slide 37 · A BPH nodule combines multiple components

Glandular

Small to cystically dilated lumina

Epithelial

Secretory and basal layers

Architectural

Papillary epithelial infoldings

Stromal

Bland spindle-shaped cells

Slide 38 · Large glands may develop ischemic injury

Pronounced enlargement

Vascular compromise

Prostatic infarction

Marked enlargement may compromise local vascular supply.

Infarction can occur in markedly enlarged prostates.

Slide 39 · Squamous metaplasia can border infarction

Infarction

Adjacent epithelial injury

Squamous metaplasia

Squamous metaplasia adjacent to prostatic infarcts.

The finding should be interpreted in the context of local injury.

Slide 40 · Benign morphology and symptoms are different dimensions

Pathology finding

Functional consequence

Nodules of glands and fibromuscular stroma

Urethral narrowing may impede urine flow

Preserved epithelial cell layers

No implication that BPH is premalignant

Variable glandular/stromal proportions

Both bulk and smooth muscle tone influence obstruction

Slide 41 · Obstruction has a static and dynamic component

Static

Tissue expansion → lumen compression

Dynamic

Stromal smooth muscle contraction → extra resistance

Mechanical narrowing reflects anatomic enlargement.

Smooth muscle contraction adds a dynamic component to outlet resistance.

Slide 42 · Outflow resistance makes bladder emptying harder

Outlet resistance

Impaired voiding

Residual urine

Urine must pass through a narrowed prostatic outlet.

Obstruction promotes incomplete emptying and retention.

Slide 43 · The bladder responds with muscle hypertrophy

Chronic resistance

Bladder muscular hypertrophy

Distention / retention

Sustained resistance drives increased work by the detrusor.

Muscular wall hypertrophy with bladder distention.

Slide 44 · Residual urine creates a path for infection

Incomplete emptying

Residual urine

Bacterial infection risk

Incomplete emptying leaves residual urine after voiding.

Retained urine can serve as a reservoir for bacterial infection.

Slide 45 · Obstructive symptoms reflect impaired flow

Difficulty initiating

Hesitancy at the start of voiding

Difficulty stopping

Interrupted / difficult-to-control stream

Overflow dribbling

Leakage associated with retention

Slide 46 · Storage symptoms accompany BPH

Frequency

Repeated need to void

Nocturia

Need to void during the night

Clinical meaning

Symptoms coexist with outlet obstruction

Slide 47 · Dysuria can coexist with obstruction

Obstruction + urinary infection

Symptoms may overlap

Painful micturition (dysuria) appears among reported features.

Concurrent bacterial urinary infection is an important potential contributor.

Symptoms require clinicopathologic assessment, not morphology alone.

Slide 48 · Infections may involve bladder or kidney

Retention / residual urine

Bladder infection

Possible upper tract infection

BPH predisposes to recurrent bacterial urinary tract infections.

Bladder and renal infections are both noted in the Robbins description.

Slide 49 · Acute retention is a clinical emergency

Acute outlet obstruction

Urinary retention

Urgent catheter relief

Sudden inability to void can complicate BPH.

Urgent catheterization to relieve acute retention.

Slide 50 · Clinical manifestations follow a causal chain

Anatomic / dynamic

Gland enlargement + smooth muscle contraction

Bladder response

Muscle hypertrophy; Retention / distention

Patient impact

Voiding symptoms, frequency/nocturia, infection risk

Relate each symptom to outlet resistance or its sequelae.

Nodularity alone does not determine the complete symptom burden.

Slide 51 · α₁-adrenergic blockers target smooth muscle tone

α₁-receptor blockade

Reduced muscle tone

Improved outlet relaxation

Blocking α₁-adrenergic signaling relaxes prostatic smooth muscle.

This targets the dynamic component of urinary outlet resistance.

Slide 52 · 5α-reductase inhibitors target DHT synthesis

5α-reductase inhibition

Less DHT

Reduced gland size

Reduction of DHT production decreases the androgen stimulus.

Resulting physical reduction in prostate size.

Slide 53 · The two drug classes treat distinct mechanisms

α₁-adrenergic blocker

5α-reductase inhibitor

Primary target: Muscle tone

Primary target: Androgen conversion

Reduces dynamic component

Reduces DHT-dependent tissue growth

Physiologic outlet relaxation

Anatomic reduction of prostate size

Slide 54 · Procedures address persistent obstruction

Persistent symptomatic BPH

Interventional option

Less outlet obstruction

Moderate or severe disease resistant to medical therapy may require a procedure.

The aim is to reduce obstructing prostatic tissue.

Slide 55 · TURP is a foundational procedural approach

Tissue reduction

Less urethral compression

Transurethral resection removes obstructing prostate tissue.

TURP as the longstanding procedural standard.

The textbook also lists alternative tissue-reduction strategies.

Slide 56 · Alternative procedural methods vary

Energy / approach

Examples

Ultrasound-based

High-intensity focused ultrasound (HIFU)

Laser and thermal

Laser therapy; Hyperthermia

Endoscopic / thermal

Transurethral electrovaporization

Other energy-based

Radiofrequency ablation

Slide 57 · A case of progressive voiding symptoms

Teaching vignette

An older adult reports hesitancy, nocturia, an interrupted stream and persistent post-void sensation of incomplete emptying.

Which tissue-level process best explains the combined findings?

Transition-zone nodules plus prostatic smooth muscle tone

Direct evolution of BPH into carcinoma

Isolated peripheral-zone growth without outlet effect

Slide 58 · Case interpretation: Outflow resistance

Correct: Transition-zone nodules + dynamic muscle tone

Transition-zone nodules compress the urethra.

Stromal smooth muscle contraction adds functional resistance.

Retention accounts for incomplete emptying; Symptom pattern fits BPH.

Slide 59 · A case of abrupt inability to void

Teaching vignette

A person with longstanding obstructive voiding complaints develops sudden, painful inability to pass urine.

What BPH-related complication requires immediate relief?

Acute urinary retention

Prostatic intraepithelial neoplasia

Uncomplicated microscopic nodularity

Slide 60 · Case interpretation: Acute urinary retention

Correct: Acute urinary retention

Sudden complete inability to void indicates acute retention.

The immediate consequence is obstructive bladder distention.

Emergency catheterization for relief.

Slide 61 · Morphology recognition exercise

Teaching vignette

A transition-zone nodule contains variably enlarged glands, papillary luminal infoldings and intervening bland spindle cells. Two epithelial layers are appreciable.

Which diagnosis is most consistent with this described morphology?

Benign prostatic hyperplasia

A malignant glandular neoplasm on morphology alone

A purely inflammatory prostate lesion

Slide 62 · Morphology recognition: BPH

Correct: Benign prostatic hyperplasia

Nodular admixture of glands and stroma is characteristic.

Variable gland size and papillary infoldings fit BPH.

Two epithelial layers and bland stroma support benign architecture.

Slide 63 · Synthesis: One anatomic location drives obstruction

Transition-zone hyperplasia

Urethral compression

Bladder outflow resistance

The clinically decisive site is the transition/periurethral region.

Benign tissue accumulation may compromise the urethral lumen.

Slide 64 · Synthesis: Hormones, histology and function

Hormones

DHT–AR + estrogen-related influences

Growth

Stromal proliferation; Epithelial survival

Morphology

Benign glandular / stromal nodules

Consequence

Urinary obstruction and retention

Slide 65 · Five core principles

BPH is common with aging and is not premalignant.

DHT–AR signaling and stromal–epithelial factors are central.

Transition-zone nodules comprise benign glands and stroma.

Enlargement plus smooth muscle tone obstructs urinary outflow.

Treatment targets muscle tone, DHT synthesis or obstructing tissue.